About
Implantica is a Swiss MedTech company founded in 2015 by Dr. Peter Forsell. The company specializes in developing innovative smart medical implants that utilize a proprietary wireless energizing platform. This technology allows for the remote powering and recharging of implants through intact skin, enabling advancements in medical implant capabilities. Implantica's product pipeline focuses on urology and gastrointestinal surgery. Key developments include AppetiteControl™, an implant for obesity management, UriControl®, a remote-controlled device for urinary incontinence, and UriRestore®, which assists patients with urinary retention. The company has also created RefluxStop™, a device for treating gastroesophageal reflux disease (GERD), which has completed clinical trials and is in the reimbursement application process in Germany. With a strong patent portfolio and a commitment to collaboration with medical experts, Implantica aims to enhance patient outcomes and quality of life through its advanced implant technologies. The company is publicly listed on Nasdaq First North Premier Growth Market under the ticker IMP A SDB.
Technologies
Keywords
Company Information
- Employees50
- Founded2003
- Annual Revenue$2017000
- Total Funding$58954300
Location
24 Industriestrasse, Zug, Zug, Switzerland, 6300
